ES2101082T3 - Composiciones de liberacion controlada. - Google Patents

Composiciones de liberacion controlada.

Info

Publication number
ES2101082T3
ES2101082T3 ES92902527T ES92902527T ES2101082T3 ES 2101082 T3 ES2101082 T3 ES 2101082T3 ES 92902527 T ES92902527 T ES 92902527T ES 92902527 T ES92902527 T ES 92902527T ES 2101082 T3 ES2101082 T3 ES 2101082T3
Authority
ES
Spain
Prior art keywords
controlled release
release compositions
core
vinylpyrolidine
caolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902527T
Other languages
English (en)
Inventor
John Michael Newton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Application granted granted Critical
Publication of ES2101082T3 publication Critical patent/ES2101082T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)

Abstract

UNA COMPOSICION DE LIBERACION CONTROLADA QUE COMPRENDE UN NUCLEO EXTRUIDO DE MATERIAL ACTIVO Y EXCIPIENTES, EN DONDE DICHO NUCLEO ESTA REVESTIDO POR UN REVESTIMIENTO INSOLUBLE EN AGUA. PREFERENTEMENTE EL NUCLEO CONTIENE UN AGENTE ACTIVO FARMACEUTICAMENTE ADECUADO JUNTO CON CELULOSA MICROCRISTALINA, UNA ARCILLA TAL COMO CAOLIN Y UN AGLUTINANTE TAL COMO POLI(VINILPIRROLIDINA).
ES92902527T 1990-11-22 1991-11-21 Composiciones de liberacion controlada. Expired - Lifetime ES2101082T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909025372A GB9025372D0 (en) 1990-11-22 1990-11-22 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
ES2101082T3 true ES2101082T3 (es) 1997-07-01

Family

ID=10685781

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902527T Expired - Lifetime ES2101082T3 (es) 1990-11-22 1991-11-21 Composiciones de liberacion controlada.

Country Status (14)

Country Link
EP (1) EP0559813B1 (es)
JP (1) JPH06502636A (es)
KR (1) KR930701984A (es)
AT (1) ATE151283T1 (es)
AU (1) AU653372B2 (es)
CA (1) CA2096733A1 (es)
DE (1) DE69125619T2 (es)
ES (1) ES2101082T3 (es)
FI (1) FI932320L (es)
GB (2) GB9025372D0 (es)
HU (1) HUT65756A (es)
NO (1) NO931859L (es)
WO (1) WO1992009270A1 (es)
ZA (1) ZA919185B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
TW246635B (es) * 1992-10-08 1995-05-01 Shell Internat Res Schappej B V
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
DE19649100A1 (de) * 1996-11-27 1998-06-04 Lohmann Therapie Syst Lts Verfahren zur verlustarmen Herstellung wirkstoffhaltiger scheibenförmiger Formkörper und diese enthaltende transdermale therapeutische Systeme
AU3024399A (en) 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
AU764469B2 (en) 1999-01-29 2003-08-21 Disphar International B.V. Pharmaceutical compositions
AU2001289653A1 (en) * 2000-07-14 2002-01-30 Universiteit Gent Composite solid shaped articles for the controlled delivery of biologically active ingredients
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20030203027A1 (en) * 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
EP1610768B1 (en) 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
MX2012010229A (es) * 2010-03-04 2012-12-05 Wockhardt Ltd Forma de dosis de liberacion modificada.
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR102637575B1 (ko) * 2016-10-05 2024-02-20 타이탄 파머슈티컬즈 인코퍼레이티드 버스트 방출이 감소된 약물 전달용 이식 가능한 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
GB2170104A (en) * 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
IE861284L (en) * 1986-05-14 1987-11-14 Birex Res And Dev Ltd And Carm Controlled release ketoprofen.
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments

Also Published As

Publication number Publication date
FI932320A7 (fi) 1993-07-09
GB9025372D0 (en) 1991-01-09
AU653372B2 (en) 1994-09-29
HUT65756A (en) 1994-07-28
GB2249957A (en) 1992-05-27
JPH06502636A (ja) 1994-03-24
AU8909691A (en) 1992-06-25
DE69125619T2 (de) 1997-09-11
NO931859L (no) 1993-07-21
ATE151283T1 (de) 1997-04-15
KR930701984A (ko) 1993-09-08
HU9301499D0 (en) 1993-09-28
CA2096733A1 (en) 1992-05-23
WO1992009270A1 (en) 1992-06-11
NO931859D0 (no) 1993-05-21
GB9124776D0 (en) 1992-01-15
EP0559813A1 (en) 1993-09-15
FI932320L (fi) 1993-07-09
DE69125619D1 (de) 1997-05-15
EP0559813B1 (en) 1997-04-09
ZA919185B (en) 1992-09-30
GB2249957B (en) 1994-11-23
FI932320A0 (fi) 1993-05-21

Similar Documents

Publication Publication Date Title
ZA919185B (en) Controlled release compositions
ES2094694B1 (es) Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
AR001405A1 (es) Formulación oral de 2-metil-tieno-beno-diacepina.
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
ES2145557T3 (es) Composiciones de ablandamiento del agua y composiciones detergentes.
AR003908A1 (es) Tableta de liberacion controlada
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
ATE268593T1 (de) Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
ID27504A (id) Formulasi oral baru
ATE186211T1 (de) Verfahren zu herstellung einer manteltablette mit spitzem kern
PE4796A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ECSP003781A (es) Recubrimiento
NO20016346L (no) Ny formulering
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
PE58999A1 (es) Tabletas de oxacarbazepina recubiertas de pelicula
ATE306254T1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
NO20052515L (no) Frigjoringskontrollerte sammensetninger
CO5251434A1 (es) Composicion de liberacion controlada
ES2175362T3 (es) Agente fitosanitario solido.
ES2046852T3 (es) Un procedimiento para preparar un champu.
ES2121779T3 (es) Utilizacion de espiperona como agente inmunosupresor y antiinflamatorio.
ES2060293T3 (es) Nueva sustancia antiulcerosa.
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 559813

Country of ref document: ES